Abstract:

Objective   To investigate the relationship between expressions of nuclear receptor interacting protein 3 (NRIP3) and distant metastasis-free survival (DMFS) in lymph node negative breast cancer. Methods   Affymetrix microarray datas of 165 breast cancer patients were analyzed by BRB-Array Tools to evaluate the NRIP3 expression. Follow-up data were handled by Kapla-Meier survival analysis and multivariate Cox regression analysis. Results   The median DMFS of the high, medium and low NRIP3 expression groups was 3980±331 days, 4391±246 days and 4518±147 days respectively. Multivariate Cox regression analysis showed that NRIP3 was the independent prognostic marker for DMFS (P＜0.01, Exp(B)=0.387). NRIP3 overexpression rate was 41.2%(42/102) and 0.6%(13/63) in ER positive and negative breast cancer patients respectively, and the difference between the two groups was significant. DMFS of the low NRIP3 expression group was significantly lower than the one of the medium and high expression groups in ER positive patients(χ2=7.268, P＜0.05).But there was no difference of DMFS among the three groups in ER negative breast cancers patients(χ2=0.524, P＞0.05). Conclusion   Over-expression of NRIP3 can inhibit metastasis in lymph node negative breast cancer patients, and its relationship with ER expression and endocrine therapy deserve further study.

Key words: Nuclear receptor interacting protein 3; Breast cancer; Metastasis